The Pharmacy and Poisons Board (PPB) has warned Kenyans about a suspicious batch of falsified Herceptin 440mg (Trastuzumab 440mg) product that has been detected in the market.
Herceptin 440mg is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It is used to treat certain types of breast cancer or stomach cancer.
According to PPB, the product batch is a confirmed counterfeit and not authorized to be in the market. The brand owner, PPB added, has confirmed that the product has falsified contents, packaging and labelling aspects.
The drug is claimed to be manufactured in Germany by Roche Products Ltd, bearing the Batch number C5830083 with a manufacturing date of the flagged drug of December 2021, and the expiry date of November 2024.
“The public is notified that this specific product batch number C5830083 is a confirmed counterfeit. It is not authorized to be in the market and is a falsified product in view of the falsified contents, packaging and labelling aspects which have been confirmed by the brand owner,” indicated the board.
Also Read: KEBS to Investigate Uji Power, Okra Amid Sexual Benefits Craze
PPB Warning to Kenyans Against Use
In addition, the board asked Kenyans to refrain from using, selling or supplying the batch as its quality could not be ascertained.
“Consequently, the PPB cautions the public against the use, supply, sale or distribution of the product batch number C5830083 as their safety, quality and efficacy CANNOT be assured,” added the board.
Further, PPB in collaboration with government investigative agencies, has instituted legal and regulatory actions against individuals suspected to be supplying and making the counterfeit product.
Also Read: Poisons Board Arrests 77 People in Illegal Pharmacies Crackdown
Also, the board noted that it had initiated a rapid response and surveillance of the market to ensure that safety and public health is protected.
“PPB in collaboration with government investigative agencies has instituted legal and regulatory actions against individuals suspected to be perpetrating the illegal activities in contravention of the Pharmacy and Poisons Act (Cap. 244).
“Furthermore, we would like to assure the public that PPB has established robust market surveillance and control system that continuously monitor the quality and safety of medical products in the Kenyan market,” explained the notice.
Follow our WhatsApp Channel for real-time news updates:
https://whatsapp.com/channel/0029VaB3k54HltYFiQ1f2i2C
